Published in Medical Patent Law Weekly, February 7th, 2007
The new Pharmacor report Emerging Antibacterial Agents finds that Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic, Daiichi-Sankyo's Cravit, Merck's Primaxin, Abbott's Omnicef, AstraZeneca's Merrem, and Wyeth's Zosyn together generated more than $4 billion in sales in 2005. All of these drugs, which represented more than 20% of the entire antibacterial drug market in 2005, will lose patent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly